Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 38Gynecologic 2Head & Neck 1Breast 1

Conditions

Ovarian Neoplasms 3Stomach Neoplasms 2Pancreatic Neoplasms 2Fallopian Tube Neoplasms 2Colorectal Neoplasms 2Triple Negative Breast Neoplasms 1Peritoneal Neoplasms 1Head and Neck Neoplasms 1Cholangiocarcinoma 1Carcinoma, Ovarian Epithelial 1Bile Duct Neoplasms 1Appendiceal Neoplasms 1

Interventions

pembrolizumab 27Cyclophosphamide 14Gemcitabine 13fludarabine 11Carboplatin 10aldesleukin 9Trastuzumab 9Specimen Handling 9Nivolumab 9Magnetic Resonance Spectroscopy 8Biopsy 8olaparib 7Cisplatin 7Paclitaxel 6palbociclib 5atezolizumab 5Taxes 5Early Intervention, Educational 5Oxaliplatin 4Methods 4Irinotecan 4Drug Therapy 4Docetaxel 4Cetuximab 4Capecitabine 4Bevacizumab 4Albumin-Bound Paclitaxel 4talazoparib 3spartalizumab 3pertuzumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Pancreatic Neoplasms × irinotecan sucrosofate × Gynecologic × Clear all
NCT05277766 2025-07-01

PIPAC-NAL-IRI

University Hospital, Ghent

Phase 1 Recruiting
45 enrolled
GastrointestinalGynecologic

Appendiceal Neoplasms, Bile Duct Neoplasms, Pancreatic Neoplasms, Peritoneal Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT01770353 2019-11-27

MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment

Ipsen

Phase 1 Completed
45 enrolled 33 charts
BreastGastrointestinalGynecologicHead & Neck

Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡